{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:03:05Z","timestamp":1761102185209},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,10]],"date-time":"2015-10-10T00:00:00Z","timestamp":1444435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00431-015-2646-x","type":"journal-article","created":{"date-parts":[[2015,10,10]],"date-time":"2015-10-10T03:30:52Z","timestamp":1444447852000},"page":"427-431","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease"],"prefix":"10.1007","volume":"175","author":[{"given":"Takahiro","family":"Kanai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takane","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Odaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Betsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,10]]},"reference":[{"key":"2646_CR1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"2646_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52:353\u2013358","journal-title":"J Med Genet"},{"key":"2646_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/8904_2011_14","volume":"1","author":"T Kanai","year":"2011","unstructured":"Kanai T, Yamagata T, Ito T, Odaka J, Saito T, Aoyagi J, Kobayashi M, Ohashi T, Ueda Y, Momoi MY (2011) Foot process effacement with normal urinalysis in classic Fabry disease. JIMD Rep 1:39\u201342","journal-title":"JIMD Rep"},{"key":"2646_CR4","first-page":"450","volume":"22","author":"H Kawachi","year":"2009","unstructured":"Kawachi H, Han GD, Miyauchi N, Hashimoto T, Suzuki K, Shimizu F (2009) Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy. J Nephrol 22:450\u2013456","journal-title":"J Nephrol"},{"key":"2646_CR5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","volume":"11","author":"JC Lubanda","year":"2009","unstructured":"Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11:256\u2013264","journal-title":"Genet Med"},{"key":"2646_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","volume":"6","author":"BE Smid","year":"2011","unstructured":"Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6:69","journal-title":"Orphanet J Rare Dis"},{"key":"2646_CR7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C Tondel","year":"2013","unstructured":"Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137\u2013148","journal-title":"J Am Soc Nephrol"},{"key":"2646_CR8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","volume":"129","author":"C Tondel","year":"2015","unstructured":"Tondel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E (2015) Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron Physiol 129:16\u201321","journal-title":"Nephron Physiol"},{"key":"2646_CR9","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS One 2:e598","journal-title":"PLoS One"},{"key":"2646_CR10","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1159\/000342369","volume":"121","author":"L Wang","year":"2012","unstructured":"Wang L, Tang Y, Howell DN, Ruiz P, Spurney RF (2012) A novel mouse model of podocyte depletion. Nephron Exp Nephrol 121:e10\u2013e22","journal-title":"Nephron Exp Nephrol"},{"key":"2646_CR11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","volume":"25","author":"DG Warnock","year":"2014","unstructured":"Warnock DG, Mauer M (2014) Fabry disease: dose matters. J Am Soc Nephrol 25:653\u2013655","journal-title":"J Am Soc Nephrol"},{"key":"2646_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.semnephrol.2009.07.012","volume":"29","author":"J Wiggins","year":"2009","unstructured":"Wiggins J (2009) Podocytes and glomerular function with aging. Semin Nephrol 29:587\u2013593","journal-title":"Semin Nephrol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-015-2646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-015-2646-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-015-2646-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:32:08Z","timestamp":1559082728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-015-2646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,10]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2646"],"URL":"https:\/\/doi.org\/10.1007\/s00431-015-2646-x","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,10]]}}}